Non-Classical HLA-G Antigen and Its Role in the Cancer Progression

REFERENCES

• Paul P., Rouas-Freiss N., Khalil-Daher I., Moreau P., Riteau B., et al. HLA-G expression in melanoma, a way for tumor cells to escape from immunosurveillance. Proc. Natl. Acad. Sci. USA. 1998; 95(8)4510–4515, [CSA]
   PubMed Web of Science ®Google Scholar
• Agrawal S., Pandey M. K. The potential role of HLA-G polymorphism in maternal tolerance to the developing fetus. J. Hemat. Stem Cell Res. 2003; 12(6)749–756, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Rouas-Freiss N., Moreau P., Menier C., Carosella E. D. HLA-G in cancer, a way to turn off the immune system. Semin. Cancer Biol. 2003; 13(5)325–336, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Boon T., Cerottini J. C., Van den Eynde B., Van der Bruggen P., Van Pel A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 1994; 12: 337–365, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• de Vries T. J., Fourkour A., Wobbes T., Verkroost G., Ruiter D. J., van Muijen G. N. Heterogeneous expression of immunotherapy candidate proteins gp100; MART-1 and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res. 1997; 57(15)3223–3229, [CSA]
   PubMed Web of Science ®Google Scholar
• Garrido F., Ruiz-Cabello F., Cabrera T., Perez-Villar J. J., Lopez-Botet M., Duggan-Keen M., Stern P. L. Implications for immunosurvillance of altered HLA class I phenotypes in the tumors. Immunol. Today 1997; 18(2)89–95, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Hicklin D. J., Wang Z., Arienti F., Rivoltini L., Parmiani G., Ferrone S. β-2 microglobulin mutations; HLA class I antigen loss; and tumor progression in melanoma. J. Clin. Invest. 1998; 101(12)2720–2729, [CSA]
   PubMed Web of Science ®Google Scholar
• Ramal L. M., Maleno I., Cabrera T., Collado A., et al. Molecular strategies to define HLA haplotype loss in micro dissected tumor cells. Hum. Immunol. 2000; 61(10)1001–1012, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Korkolopoulou P., Kaklamanis L., Pezzella F., Harris A. L., Gatter K. C. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br. J. Cancer 1996; 73(2)148–153, [CSA]
   PubMed Web of Science ®Google Scholar
• Sanda M. G., Restifo N. P., Walsh J. C., Kawakami Y., Nelson W. G., et al. Molecular characterization of defective antigen processing in human prostate cancer. J. Natl. Cancer Inst. 1995; 87(4)280–285, [CSA]
   PubMed Web of Science ®Google Scholar
• Seliger B., Hohne A., Jung D., Kallfelz M., Knuth A., et al. Expression and function of the peptide transporters in escape variants of human renal cell carcinomas. Exp. Hematol. 1997; 25(7)608–614, [CSA]
   PubMed Web of Science ®Google Scholar
• Soong T. W., Hui K. M. Locus-specific transcriptional control of HLA genes. J. Immunol. 1992; 149(6)2008–2020, [CSA]
   PubMed Web of Science ®Google Scholar
• Garrido F., Cabrera T., Lopez-Nevot M. A., Ruiz-Cabello F. HLA class I antigens in human tumors. Adv. Cancer Res. 1995; 67: 155–195, [CSA]
   PubMed Web of Science ®Google Scholar
• Marincola F. M., Jaffee E. M., Hicklin D. J., Ferrone S. Escape of human solid tumors from T-cell recognition, molecular mechanisms and functional significance. Adv. Immunol. 2000; 74: 181–273, [CSA]
   PubMedGoogle Scholar
• Stern P. L., Rinke de Wit T. F. The role of MHC class I expression in developmental tumours. Semin. Cancer Biol. 1991; 2(1)11–16, [CSA]
   PubMedGoogle Scholar
• Cabrera T., Angustias Fernandez M., Sierra A., Garrido A., Herruzo A., et al. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum. Immunol. 1996; 50(2)127–134, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bontkes H. J., Walboomers J. M., Meijer C. J., Helmerhorst T. J., Stern P. L. Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression. Lancet 1998; 351(9097)187–188, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ljunggren H. G., Karre K. In search of the ‘missing self’, MHC molecules and NK cell recognition. Immunol. Today 1990; 11(7)237–244, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Dunn G. P., Bruce A. T., Ikeda H., Old L. J., Schreiber R. D. Cancer immunoediting, from immunosurveillance to tumor escape. Nat. Immunol. 2002; 3(11)991–998, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Girardi M., Oppenheim D. E., Steele C. R., Lewis J. M., Glusac E., et al. Regulation of cutaneous malignancy by gammadelta T cells. Science 2001; 294(5542)605–609, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Street S. E., Trapani J. A., MacGregor D., Smyth M. J. Suppression of lymphoma and epithelial malignancies affected by interferon gamma. J. Exp. Med. 2002; 196(1)129–134, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Shankaran V., Ikeda H., Bruce A. T., White J. M., Swanson P. E., Old L. J., Schreiber R. D. IFN gamma and lymphocytes prevent primary tumors development and shape tumors immunogenicity. Nature 2001; 410(6832)1107–1111, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Takeda K., Smyth M. J., Cretney E., Hayakawa Y., Kayagaki N., Yagita H., Okumura K. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 2002; 195(2)161–169, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gerosa F., Baldani-Guerra B., Nisii C., Marchesini V., Carra G., Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 2002; 195(3)327–333, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Apte R. S., Mayhew E., Niederkorn J. Y. Local inhibition of natural killer cell activity promotes the progressive growth of intra ocular tumors. Invest. Ophthalmol. Vis. Sci. 1997; 38(6)1277–1282, [CSA]
   PubMed Web of Science ®Google Scholar
• Oyama T., Ran S., Ishida T., Nadaf S., Kerr L., et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J. Immunol. 1998; 160(3)1224–1232, [CSA]
   PubMed Web of Science ®Google Scholar
• Girolomoni G., Ricciardi-Castagnoli P. Dendritic cells hold promise for immunotherapy. Immunol. Today 1997; 18(3)102–104, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Zeidler R., Eissner G., Meissner P., Uebel S., Tampe R., et al. Down regulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. Blood 1997; 90(6)2390–2397, [CSA]
   PubMed Web of Science ®Google Scholar
• Van d en, Eynde B., Gaugler B., van der Bruggen P., Coulie P., Brichard V., Boon T. Human tumour antigens recognized by T-cells, Perspectives for new cancer vaccines. Biochem. Soc. Trans. 1995; 23(3)681–686, [CSA]
   PubMed Web of Science ®Google Scholar
• Zaks T. Z., Chappell D. B., Rosenberg S. A., Restifo N. P. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor, selective rescue by caspase inhibition. J. Immunol. 1999; 162(6)3273–3279, [CSA]
   PubMed Web of Science ®Google Scholar
• Urosevic M., Kurrer M. O., Kamarashev J., Mueller B., Weder W., et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology; human leukocyte antigen class I loss and interleukin-10 production. Am. J. Pathol. 2001; 159(3)817–824, [CSA]
   PubMed Web of Science ®Google Scholar
• Fukushima Y., Oshika Y., Nakamura M., Tokunaga T., Hatanaka H., et al. Increased expression of human histocompatibility leukocyte antigen-G in colorectal cancer cells. Int. J. Mol. Med. 1998; 2(3)349–351, [CSA]
   PubMed Web of Science ®Google Scholar
• Wagner S. N., Rebmann V., Willers C. P., Grosse-Wilde H., Goos M. Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma. Lancet 2000; 356(9225)220–221, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Urosevic M., Willers J., Mueller B., Kempf W., Burg G., Dummer R. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood 2002; 99(2)609–617, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lefebvre S., Antoine M., Uzan S., McMaster M., Dausset J., Carosella E. D., Paul P. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J. Pathol. 2002; 196(3)266–274, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ibrahim E. C., Guerra N., Lacombe M. J., Angevin E., Chouaib S., Carosella E. D., Caignard A., Paul P. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res. 2001; 61(18)6838–6845, [CSA]
   PubMed Web of Science ®Google Scholar
• Wiendl H., Mitsdoerffer M., Hofmeister V., Wischhusen J., Bornemann A., Meyermann R., Weiss E. H., Melms A., Weller M. A functional role of HLA-G expression in human gliomas, an alternative strategy of immune escape. J. Immunol. 2002; 168(9)4772–4780, [CSA]
   PubMed Web of Science ®Google Scholar
• Carosella E. D., Paul P., Moreau P., Rouas-Freiss N. HLA-G and -E,fundamental and physiological aspects. Immunol. Today 2000; 21(11)532–534, [CSA], [CROSSREF]
   Google Scholar
• Maier S., Geraghty D. E., Weiss E. H. Expression and regulation of HLA-G in human glioma cell lines. Transplant. Proc. 1999; 31(4)1849–1853, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Paul P., Cabestre F. A., Le Gal F. A., Khalil Daher I., Le Danff C., et al. Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res 1999; 59(8)1954–1960, [CSA]
   PubMed Web of Science ®Google Scholar
• Hamai Y., Fujii T., Yamashita T., Miki A., Hyodo H., et al. The expression of human leukocyte antigen-G on trophoblasts abolishes the growth-suppressing effect of interleukin-2 toward them. Am. J. Reprod. Immunol. 1999; 41(2)153–158, [CSA]
   PubMed Web of Science ®Google Scholar
• Pangault C., Amiot L., Caulet-Maugendre S., Brasseur F., Burtin F., et al. HLA-G protein expression is not induced during malignant transformation. Tissue Antigens 1999; 53(4 Pt.1)335–346, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Adrian Cabestre F., Moreau P., Riteau B., Ibrahim E. C., Le Danff C., et al. HLA-G expression in human melanoma cells: protection from NK cytolysis. J. Reprod. Immunol. 1999; 43(2)183–193, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Riteau B., Faure F., Menier C., Viel S., Carosella E. D., et al. Exosomes bearing HLA-G are released by melanoma cells. Hum. Immunol. 2003; 64(11)1064–1072, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kirszenbaum M., Djoulah S., Hors J., Prost S., Dausset J., Carosella E. D. Polymorphism of HLA-G gene and protein. J. Reprod. Immunol. 1999; 43(2)105–109, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ishitani A., Geraghty D. E. Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc. Natl. Acad. Sci. USA. 1992; 89(9)3947–3951, [CSA]
   PubMed Web of Science ®Google Scholar
• Paul P., Cabestre F. A., Ibrahim E. C., Lefebvre S., Khalil-Daher I., et al. Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5; -G6; and -G7 transcripts in human transfected cells. Hum. Immunol. 2000; 61(11)1138–1149, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sanders SK, Giblin P. A., Kavathas P. Cell-cell adhesion mediated by CD8 and human histocompatibility leukocyte antigen G; a nonclassical major histocompatibility complex class 1 molecule on cytotrophoblasts. J. Exp. Med. 1991; 174(3)737–740, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lee N., Malacko A. R., Ishitani A., Chen M. C., Bajorath J., et al. The membrane-bound and soluble forms of HLA-G bind identical sets of endogenous peptides but differ with respect to TAP association. Immunity 1995; 3(5)591–600, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Rouas-Freiss N., Moreau P., Menier C. Carosella. E/D. HLA-G in cancer, a way to turn off the immune system. Semin. Cancer. Biol. 2003; 13(5)325–336, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Aractingi S., Kanitakis J., Euvrard S., Le Danff C., Carosella E. D. Selective expression of HLA-G in malignant and premalignant skin specimens in kidney transplant recipients. Int. J. Cancer. 2003; 106(2)232–235, [CSA]
   PubMed Web of Science ®Google Scholar
• Rajagopalan S., Long E. O. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J. Exp. Med. 1999; 189(7)1093–1100, [CSA]
   PubMed Web of Science ®Google Scholar
• Ponte M., Cantoni C., Biassoni R., Tradori-Cappai A., Bentivoglio G., et al. Inhibitory receptors sensing HLA-G1 molecules in pregnancy, decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49; an HLA-G1-specific receptor. Proc. Natl. Acad. Sci. USA. 1999; 96(10)5674–5679, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Navarro F., Llano M., Bellon T., Colonna M., Geraghty D. E., Lopez-Botet M. The ILT2 (LIR1) and CD94/NKG2A NK cellreceptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells. Eur. J. Immunol. 1999; 29(1)277–283, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Colonna M., Samaridis J., Cella M., Angmanm L., Allenm R. L., et al. Cutting edge: human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J. Immunol. 1998; 160(7)3096–3100, [CSA]
   PubMed Web of Science ®Google Scholar
• Borrego F., Ulbrecht M., Weiss E. H., Coligan J. E., Brooks A. G. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J. Exp. Med. 1998; 187(5)813–818, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Riteau B., Menier C., Khalil-Daher I., Martinozzi S., Pla M., et al. HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. Int. Immunol. 2001; 13(2)193–201, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Menier C., Riteau B., Carosella E. D., Rouas-Freiss N. The MICA triggering signal for NK cell tumor lysis is counteracted by HLA-G1-mediated inhibitory signal. Int. J. Cancer. 2002; 100(1)63–70, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Vyas Y. M., Mehta K. M., Morgan M., Maniar H., Butros L., et al. Spatial organization of signal transduction molecules in the NK cell immune synapses during MHC class I-regulated non-cytolytic and cytolytic interactions. J. Immunol. 2001; 167(8)4358–4367, [CSA]
   PubMed Web of Science ®Google Scholar
• Forte P., Pazmany L., Matter-Reissmann U. B., Stussi G., Schneider M. K., Seebach J. D. HLA-G inhibits rolling adhesion of activated human NK cells on porcine endothelial cells. J. Immunol. 2001; 167(10)6002–6008, [CSA]
   PubMed Web of Science ®Google Scholar
• Dorling A., Monk N., Lechler R. HLA-G inhibits the transendothelial cell migration of human NK cells, a strategy for inhibiting xenograft rejection. Transplant. Proc. 2000; 32(5)938, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fournel S., Aguerre-Girr M., Huc X., Lenfant F., Alam A., Toubert A., et al. Cutting edge, soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J. Immunol. 2000; 164(12)6100–6104, [CSA]
   PubMed Web of Science ®Google Scholar
• Bainbridge D. R., Ellis S. A., Sargent I. L. HLA-G suppresses proliferation of CD4(+) T-lymphocytes. J. Repord. Immunol. 2000; 48(1)17–26, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gobin S. J., van den Elsen P. J. Transcriptional regulation of the MHC class Ib genes HLA-E; HLA-F; and HLA-G. Hum. Immunol. 2000; 61(11)1102–1107, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gobin S. J., Keijsers V., van Zutphen M., van den Elsen P. J. The role of enhancer A in the locus-specific trans activation of classical and nonclassical HLA class I genes by nuclear factor kappa. B. J. Immunol 1998; 161(5)2276–2283, [CSA]
   Web of Science ®Google Scholar
• Lefebvre S., Berrih-Aknin S., Adrian F., Moreau P., Poea S., et al. A specific interferon (IFN)-stimulated response element of the distal HLA-G promoter binds IFN-regulatory factor 1 and mediates enhancement of this nonclassical class I gene by IFN-beta. J. Biol. Chem. 2001; 276(9)6133–6139, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ibrahim E. C., Morange M., Dausset J., Carosella E. D., Paul P. Heat shock and arsenite induce expression of the non classical class I histocompatibility HLA-G gene in tumor cell lines. Cell Stress Chaperones 2000; 5(3)207–218, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chang C. C., Ferrone S. HLA-G in melanoma, can the current controversies be solved?. Semin Cancer Biol. 2003; 13(5)361–369, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Spencer J. V., Lockridge K. M., Barry P. A., Lin G., Tsang M., Penfold M. E., Schall T. J. Potent immunosuppressive activities of cytomegalovirus encoded interleukin-10. J. Virol. 2002; 76(3)1285–1292, [CSA]
   PubMed Web of Science ®Google Scholar
• Kanai T., Fujii T., Unno N., Yamashita T., Hyodo H., et al. Human leukocyte antigen-G-expressing cells differently modulate the release of cytokines from mononuclear cells present in the deciduas versus peripheral blood. Am. J. Reprod. Immunol. 2001; 45(2)94–99, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Frumento G., Franchello S., Palmisano G. L., Nicotra M. R., Giacomini P., et al. Melanomas and melanoma cell lines do not express HLA-G; and the expression cannot be induced by gamma IFN treatment. Tissue Antigens 2000; 56(1)30–37, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Esteller M., Fraga M. F., Paz M. F., Campo E., Colomer D., et al. Cancer epigenetics and methylation. Science 2002; 297(5588)1807–1808, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Guillaudeux T., Rodriguez A. M., Girr M., Mallet V., Ellis S. A., et al. Methylation status and transcriptional expression of the MHC class I loci in human trophoblast cells from term placenta. J. Immunol. 1995; 154(7)3283–3299, [CSA]
   PubMed Web of Science ®Google Scholar
• Moreau P., Mouillot G., Rousseau P., Marcou C., Dausset J., Carosella E. D. HLA-G gene repression is reversed by demethylation. Proc. Natl. Acad. Sci. USA. 2003; 100(3)1191–1196, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Brown R., Strathdee G. Epigenomics and epigenetic therapy of cancer. Trends Mol. Med. 2002; 8(Suppl. 4)S43–S48, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Christman J K. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation, mechanistic studies and their implications for cancer therapy. Oncogene 2002; 21(35)5483–5495, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar